



October, 2009

Dear Healthcare Provider,

The FDA has alerted healthcare professionals of a revision made to the USP (United States Pharmacopeia) monograph for Heparin Sodium on October 1, 2009. As the new product is implemented, you will see both products in the market. They are both safe to use. Excelsior Medical will follow the FDA guidelines with indentifying the product manufactured under the new monograph by adding an "N" at the end of the expiration date. See illustrations below:

Healthcare providers need to be aware of the potential decrease in potency relative to product manufactured and tested according to the new USP monograph for heparin sodium. According to the FDA, the new USP reference standard and unit definition for heparin is approximately 10% less potent than the standard prior to the new revision.


For additional information, please review the FDA Alert of Health Care Professionals at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm184502.htm>

If you have any additional questions, please contact our customer service department at (800) 487-4276.

OLD USP MONOGRAPH PRODUCT



NEW USP MONOGRAPH PRODUCT



“N” Represents New

Sincerely,

John Linfante
Vice President, RA/QA